- Home
- AQST vs HCAT Comparison
AQST vs HCAT Comparison
Compare AQST & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- HCAT
- Stock Information
- Founded
- AQST 2004
- HCAT 2008
- Country
- AQST United States
- HCAT United States
- Employees
- AQST N/A
- HCAT N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- HCAT Computer Software: Programming Data Processing
- Sector
- AQST Health Care
- HCAT Technology
- Exchange
- AQST Nasdaq
- HCAT Nasdaq
- Market Cap
- AQST 274.4M
- HCAT 318.2M
- IPO Year
- AQST 2018
- HCAT 2019
- Fundamental
- Price
- AQST $3.02
- HCAT $4.55
- Analyst Decision
- AQST Strong Buy
- HCAT Buy
- Analyst Count
- AQST 7
- HCAT 11
- Target Price
- AQST $10.57
- HCAT $9.27
- AVG Volume (30 Days)
- AQST 1.3M
- HCAT 800.1K
- Earning Date
- AQST 03-05-2025
- HCAT 05-08-2025
- Dividend Yield
- AQST N/A
- HCAT N/A
- EPS Growth
- AQST N/A
- HCAT N/A
- EPS
- AQST N/A
- HCAT N/A
- Revenue
- AQST $57,561,000.00
- HCAT $306,584,000.00
- Revenue This Year
- AQST N/A
- HCAT $11.33
- Revenue Next Year
- AQST $35.72
- HCAT $9.68
- P/E Ratio
- AQST N/A
- HCAT N/A
- Revenue Growth
- AQST 13.79
- HCAT 3.60
- 52 Week Low
- AQST $2.24
- HCAT $3.76
- 52 Week High
- AQST $5.80
- HCAT $9.24
- Technical
- Relative Strength Index (RSI)
- AQST 50.92
- HCAT 46.54
- Support Level
- AQST $3.05
- HCAT $4.30
- Resistance Level
- AQST $3.24
- HCAT $4.67
- Average True Range (ATR)
- AQST 0.20
- HCAT 0.28
- MACD
- AQST 0.04
- HCAT 0.09
- Stochastic Oscillator
- AQST 57.47
- HCAT 83.33
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.